{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T02:31:53Z","timestamp":1791340313766,"version":"4.3.1"},"reference-count":100,"publisher":"Wiley","issue":"11P2","license":[{"start":{"date-parts":[[2012,1,17]],"date-time":"2012-01-17T00:00:00Z","timestamp":1326758400000},"content-version":"vor","delay-in-days":3729,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["accpjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacotherapy"],"published-print":{"date-parts":[[2001,11]]},"abstract":"<jats:p>Antibiotic pharmacodynamics is an evolving science that focuses on the relationship between drug concentration and pharmacologic effect, which is an antibiotic\u2010induced bacterial death that also can manifest as an adverse drug reaction. The pharmacologic action of antibiotics usually can be described as concentration dependent or independent, although such classifications are highly reliant on the specific antibiotic and bacterial pathogen being studied. Quantitative pharmacodynamic parameters, such as ratio of the area under the concentration\u2010time curve during a 24\u2010hour dosing period to minimum inhibitory concentration (AUC<jats:sub>0\u201324<\/jats:sub>:MIC), ratio of maximum serum antibiotic concentration to MIC (C<jats:sub>max<\/jats:sub>:MIC), and duration of time that antibiotic concentrations exceed MIC (T&gt;MIC), have been proposed as likely predictors of clinical and microbiologic success or failure for different pairings of antibiotic and bacteria. Thus far, most pharmacodynamic data reported have focused on fluoroquinolones, but work has been conducted on vancomycin, \u03b2\u2010lactams, macrolides, aminoglycosides, and other antibiotics. Despite the development of a number of different pharmacodynamic modeling systems, remarkable agreement exists between in vitro, animal, and limited human data. Although still somewhat premature and requiring additional clinical validation, antibiotic pharmacodynamics will likely advance on four fronts: the science should prove to be extremely useful and represent a cost\u2010effective and efficient method to help develop new antibiotics; formulary committees will likely use pharmacodynamic parameters to assist in differentiating antibiotics of the same chemical class in making antibiotic formulary selections; pharmacodynamic principles will likely be used to design optimal antibiotic strategies for patients with severe infections; and limited data to date suggest that the application of pharmacodynamic concepts may limit or prevent the development of antibiotic resistance. The study of antibiotic pharmacodynamics appears to hold great promise and will likely become a routine part of our daily clinical practices.<\/jats:p>","DOI":"10.1592\/phco.21.18.302s.33905","type":"journal-article","created":{"date-parts":[[2004,6,4]],"date-time":"2004-06-04T06:03:59Z","timestamp":1086329039000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":76,"title":["What Do We Really Know About Antibiotic Pharmacodynamics?"],"prefix":"10.1002","volume":"21","author":[{"given":"Brent W.","family":"Gunderson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gigi H.","family":"Ross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khalid H.","family":"Ibrahim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John C.","family":"Rotschafer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2012,1,17]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(50)90425-6"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.13.4.570"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/159.2.281"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.33.7.1046"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.30.3.403"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/154.3.511"},{"key":"e_1_2_1_8_2","doi-asserted-by":"crossref","first-page":"2414","DOI":"10.1128\/AAC.41.11.2414","article-title":"Pharmacodynamics and bactericidal activity of ceftriaxone therapy in experimental cephalosporin\u2010resistant pneumococcal meningitis","volume":"41","author":"Lutsar I.","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.14.1.6"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/0732-8893(95)00053-D"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.38.5.1112"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(84)80074-1"},{"key":"e_1_2_1_13_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/158.4.831"},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.35.7.1413"},{"key":"e_1_2_1_15_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.28.3.404"},{"key":"e_1_2_1_16_2","doi-asserted-by":"publisher","DOI":"10.1086\/514622"},{"key":"e_1_2_1_17_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02016564"},{"key":"e_1_2_1_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(79)90242-0"},{"key":"e_1_2_1_19_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1974.03240030027020"},{"key":"e_1_2_1_20_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-199835050-00004"},{"key":"e_1_2_1_21_2","first-page":"7","article-title":"Choosing an antibiotic on the basis of pharmaco\u2010dynamics","volume":"77","author":"Craig W.A.","year":"1998","journal-title":"Ear Nose Throat J"},{"key":"e_1_2_1_22_2","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1128\/AAC.42.2.231","article-title":"Pharmacodynamics of ampicillin\u2010sulbactam in an in vitro infection model against Escherichia coli strains with various levels of resistance","volume":"42","author":"Lamp K.C.","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"e_1_2_1_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0732-8893(97)00020-5"},{"key":"e_1_2_1_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0891-5520(05)70096-9"},{"key":"e_1_2_1_25_2","first-page":"391","volume-title":"Differences in time above MIC (T>MIC) required for efficacy of \u03b2\u2010lactams in animal model infections [abstr]","author":"Craig W.","year":"1993"},{"key":"e_1_2_1_26_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/27.suppl_C.29"},{"key":"e_1_2_1_27_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/155.1.93"},{"key":"e_1_2_1_28_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/29.4.427"},{"key":"e_1_2_1_29_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/150.5.778"},{"key":"e_1_2_1_30_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/162.2.408"},{"key":"e_1_2_1_31_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/158.1.7"},{"key":"e_1_2_1_32_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.31.7.1054"},{"key":"e_1_2_1_33_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/162.2.414"},{"key":"e_1_2_1_34_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.38.5.981"},{"key":"e_1_2_1_35_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/149.3.443"},{"key":"e_1_2_1_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(84)90358-9"},{"key":"e_1_2_1_37_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.1.5906.477"},{"key":"e_1_2_1_38_2","first-page":"319","article-title":"Correlation of pharmacokinetic indices with therapeutic outcome in patients receiving aminoglycosides","volume":"5","author":"Deziel\u2010Evans L.M.","year":"1986","journal-title":"Clin Pharm"},{"key":"e_1_2_1_39_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.39.3.650"},{"key":"e_1_2_1_40_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.21.3.407"},{"key":"e_1_2_1_41_2","doi-asserted-by":"publisher","DOI":"10.1177\/106002809402800618"},{"key":"e_1_2_1_42_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.36.9.1951"},{"key":"e_1_2_1_43_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.35.1.117"},{"key":"e_1_2_1_44_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.35.3.399"},{"issue":"6","key":"e_1_2_1_45_2","first-page":"S64","article-title":"Pharmacodynamic factors of antibiotic efficacy","volume":"12","author":"Rotschafer J.C.","year":"1992","journal-title":"Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy"},{"key":"e_1_2_1_46_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/164.3.499"},{"key":"e_1_2_1_47_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.40.3.627"},{"key":"e_1_2_1_48_2","first-page":"53","volume-title":"In vitro evaluation of pharmacodynamic outcome parameters for three fluoroquinolones against Streptococcus pneumoniae [abstr]","author":"Wright D.H.","year":"1998"},{"key":"e_1_2_1_49_2","first-page":"50","volume-title":"Levofloxacin pharmacodynamics vs. Streptococcus pneumoniae [abstr]","author":"Ibrahim K.H.","year":"1999"},{"key":"e_1_2_1_50_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.43.3.672"},{"key":"e_1_2_1_51_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.43.5.1118"},{"key":"e_1_2_1_52_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/43.1.79"},{"key":"e_1_2_1_53_2","first-page":"50","volume-title":"Investigation of AUC\/MIC ratio as a generic predictor of fluoroquinolone activity against Staphylococcus aureus using trovafloxacin, ciprofloxacin, sparfloxacin, and levofloxacin in an in vitro pharmacodynamic model [abstr]","author":"Hoang A.D.","year":"1998"},{"key":"e_1_2_1_54_2","first-page":"5","volume-title":"Evaluation of the activity of the newer fluoroquinolones against ciprofloxacin\u2010resistant Streptococcus pneumoniae [abstr]","author":"Coyle E.A.","year":"1999"},{"key":"e_1_2_1_55_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.44.3.598-601.2000"},{"key":"e_1_2_1_56_2","first-page":"52","volume-title":"Pharmacodynamic outcome parameters as predictors for fluoroquinolones in the treatment of anaerobic infections [abstr]","author":"Peterson M.L.","year":"1998"},{"key":"e_1_2_1_57_2","first-page":"8","volume-title":"Fluoroquinolone pharmacodynamics in Bacteroides thetaiotamicron [abstr]","author":"Brown G.H.","year":"1999"},{"key":"e_1_2_1_58_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.37.3.483"},{"key":"e_1_2_1_59_2","first-page":"9","volume-title":"In vivo pharmacodynamic activity of sitafloxacin against multiple bacterial pathogens [abstr]","author":"Andes D.R.","year":"1999"},{"key":"e_1_2_1_60_2","first-page":"10","volume-title":"In vivo pharmacodynamic activity of gatifloxacin against multiple bacterial pathogens [abstr]","author":"Andes D.R.","year":"1999"},{"key":"e_1_2_1_61_2","first-page":"8","volume-title":"In vivo pharmacodynamic activity of gemifloxacin against multiple bacterial pathogens [abstr]","author":"Andes D.R.","year":"1999"},{"key":"e_1_2_1_62_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.38.12.2730"},{"key":"e_1_2_1_63_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.37.5.1073"},{"key":"e_1_2_1_64_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.42.3.521"},{"key":"e_1_2_1_65_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.279.2.125"},{"key":"e_1_2_1_66_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/40.suppl_1.45"},{"key":"e_1_2_1_67_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.1989.00390100083020"},{"key":"e_1_2_1_68_2","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1128\/AAC.43.9.2251","article-title":"Fluoroquinolone resistance in Bacteroides fragilis following sparfloxacin exposure","volume":"43","author":"Peterson M.L.","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"key":"e_1_2_1_69_2","first-page":"134","volume-title":"Pharmacodynamics (PDs) of oral OPC\u201017116 in patients (pts) with acute bacterial exacerbations of chronic bronchitis [abstr]","author":"Forrest A.","year":"1993"},{"key":"e_1_2_1_70_2","first-page":"509","volume-title":"Pharmacodynamic comparison of clarithromycin vs erythromycin [abstr]","author":"Ebert S.","year":"1991"},{"key":"e_1_2_1_71_2","first-page":"45","volume-title":"In vivo and in vitro postantibiotic effects (PAEs) of azithromycin [abstr]","author":"Craig W.","year":"1992"},{"key":"e_1_2_1_72_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/38.4.589"},{"key":"e_1_2_1_73_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.44.5.1247-1254.2000"},{"key":"e_1_2_1_74_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.39.8.1848"},{"key":"e_1_2_1_75_2","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1128\/AAC.43.8.2005","article-title":"Evaluation of low\u2010dose, extended\u2010interval clindamycin regimens against Staphylococcus aureus and Streptococcus pneumoniae using a dynamic in vitro model of infection","volume":"43","author":"Lewis R.E.","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"key":"e_1_2_1_76_2","doi-asserted-by":"publisher","DOI":"10.1345\/aph.17299"},{"key":"e_1_2_1_77_2","doi-asserted-by":"publisher","DOI":"10.1592\/phco.19.6.404.31054"},{"key":"e_1_2_1_78_2","doi-asserted-by":"publisher","DOI":"10.1097\/00006454-199704000-00027"},{"key":"e_1_2_1_79_2","first-page":"27","volume-title":"Expanding indications for the new macrolides, azalides, and streptogramins","author":"Craig W.A.","year":"1997"},{"key":"e_1_2_1_80_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.34.10.1869"},{"key":"e_1_2_1_81_2","first-page":"631","article-title":"Vancomycin","volume":"52","author":"Geraci J.E.","year":"1977","journal-title":"Mayo Clin Proc"},{"key":"e_1_2_1_82_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.36.8.1766"},{"key":"e_1_2_1_83_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.34.12.2348"},{"key":"e_1_2_1_84_2","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1128\/AAC.41.6.1359","article-title":"Pharmacodynamics of RP 59500 (quinupristin\u2010dalfopristin) administered by intermittent versus continuous infusion against Staphylococcus aureus\u2010infected fibrin\u2010platelet clots in an in vitro infection model","volume":"41","author":"Rybak M.J.","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"key":"e_1_2_1_85_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/39.suppl_1.29"},{"key":"e_1_2_1_86_2","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1128\/AAC.42.9.2188","article-title":"Pharmacodynamic analysis of the activity of quinupristin\u2010dalfopristin against vancomycin\u2010resistant Enterococcus faecium with differing MBCs via time\u2010kill\u2010curve and postantibiotic effect methods","volume":"42","author":"Aeschlimann J.R.","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"e_1_2_1_87_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.39.2.400"},{"key":"e_1_2_1_88_2","first-page":"898","volume-title":"Bactericidal activity of semisynthetic streptogramin RP 59500 against S. aureus [abstr]","author":"Drugeon H.B.","year":"1991"},{"key":"e_1_2_1_89_2","doi-asserted-by":"publisher","DOI":"10.1086\/516284"},{"key":"e_1_2_1_90_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0149-2918(00)87978-3"},{"key":"e_1_2_1_91_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/14.6.619"},{"key":"e_1_2_1_92_2","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1128\/AAC.40.4.904","article-title":"Comparative in vitro pharmacodynamics of imipenem and meropenem against Pseudomonas aeruginosa","volume":"40","author":"White R.","year":"1996","journal-title":"Antimicrob Agents Chemother"},{"key":"e_1_2_1_93_2","first-page":"118","article-title":"Pharmacodynamics of \u03b2\u2010lactam antibiotics on gram\u2010negative bacteria: initial killing, morphology and postantibiotic effect","volume":"74","author":"Hanberger H.","year":"1990","journal-title":"Scand J Infect Dis Suppl"},{"key":"e_1_2_1_94_2","doi-asserted-by":"publisher","DOI":"10.1086\/515003"},{"key":"e_1_2_1_95_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(91)90311-K"},{"key":"e_1_2_1_96_2","doi-asserted-by":"publisher","DOI":"10.1179\/joc.1999.11.6.426"},{"key":"e_1_2_1_97_2","doi-asserted-by":"publisher","DOI":"10.1086\/503169"},{"key":"e_1_2_1_98_2","first-page":"218","volume-title":"Decreased susceptibility of anaerobic gram\u2010negative bacteria to trovafloxacin [abstr]","author":"Gustafson D.R.","year":"1999"},{"key":"e_1_2_1_99_2","first-page":"235","article-title":"Human pharmacodynamics of \u03b2\u2010lactams, aminoglycosides and their combination","volume":"74","author":"Drusano G.L.","year":"1990","journal-title":"Scand J Infect Dis Suppl"},{"key":"e_1_2_1_100_2","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1128\/AAC.43.3.592","article-title":"Synergy of an investigational glycopeptide, LY333328, with once\u2010daily gentamicin against vancomycin\u2010resistant Enterococcus faecium in a multiple\u2010dose, in vitro pharmacodynamic model","volume":"43","author":"Zelenitsky S.A.","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"key":"e_1_2_1_101_2","doi-asserted-by":"publisher","DOI":"10.1159\/000007198"}],"container-title":["Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1592%2Fphco.21.18.302S.33905","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1592\/phco.21.18.302S.33905","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T12:31:20Z","timestamp":1761049880000},"score":1,"resource":{"primary":{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/10.1592\/phco.21.18.302S.33905"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,11]]},"references-count":100,"journal-issue":{"issue":"11P2","published-print":{"date-parts":[[2001,11]]}},"alternative-id":["10.1592\/phco.21.18.302S.33905"],"URL":"https:\/\/doi.org\/10.1592\/phco.21.18.302s.33905","archive":["Portico"],"relation":{},"ISSN":["0277-0008","1875-9114"],"issn-type":[{"value":"0277-0008","type":"print"},{"value":"1875-9114","type":"electronic"}],"subject":[],"published":{"date-parts":[[2001,11]]},"assertion":[{"value":"2012-01-17","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}